Literature DB >> 10940890

Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice.

B D Hondowicz1, A Y Park, M M Elloso, P Scott.   

Abstract

BALB/c and anti-IL-12-treated C3H mice infected with Leishmania major develop a Th2 cell response. However, in contrast to BALB/c mice, C3H mice treated transiently with an anti-IL-12 monoclonal antibody switch from a Th2 to a Th1 response and resolve their lesions once treatment is terminated. We report here that the critical difference in the Th2 response between BALB/c and C3H mice is in their ability to respond to IL-12. Thus, C3H mice with a Th2 response maintain a CD4+ T cell population that expresses IL-12 receptor beta1 and beta2 mRNA and produces IFN-gamma after exposure to IL-12. These results indicate that Th2 cell populations from different genetic backgrounds differ in their stability, and that this difference can be related to differential regulation of the IL-12 receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940890     DOI: 10.1002/1521-4141(200007)30:7<2007::AID-IMMU2007>3.0.CO;2-W

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE.

Authors:  Gregory D Gregory; Shveta S Raju; Susan Winandy; Melissa A Brown
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

2.  Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors:  D Zagury; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  CD4+ Th1 cells induced by dendritic cell-based immunotherapy in mice chronically infected with Leishmania amazonensis do not promote healing.

Authors:  Yannick F Vanloubbeeck; Amanda E Ramer; Fei Jie; Douglas E Jones
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 4.  Development and regulation of cell-mediated immunity in experimental leishmaniasis.

Authors:  Phillip Scott
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Endogenous interleukin-12 is critical for controlling the late but not the early stage of Leishmania mexicana infection in C57BL/6 mice.

Authors:  Fabiola Aguilar Torrentera; Jon D Laman; Marjan Van Meurs; Luciano Adorini; Eric Muraille; Y Carlier
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

6.  Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection.

Authors:  P Kropf; S Herath; R Klemenz; I Müller
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 7.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

8.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.